Iwasaki: Yeah, There are some things that we can be contemplating for better results of clinical trials for extended COVID. So the first thing is definitely the heterogeneity of sickness and having a validated biomarker likely in to subclass the endotypes that I discussed would considerably simplify the drug growth and allow it to be attractive to